News and Conferences

Newsletters

• Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
  2023-09-21
• New validated pre-clinical model to assess treatments for post-surgical pain
  2023-08-31
• Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
  2023-08-21
• New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
  2023-08-01
• Do Your Compounds Exhibit Anti-Inflammatory Compounds
  2023-07-17
• Profile your anti-inflammatory compounds in primary human immune cells
  2023-06-28
• New EEG services from Transpharmation. Read on for results...
  2023-06-14
• Accelerate your Drug Discovery Research. Proven results, fast and cost effective
  2023-06-07
• Urgent Treatments Needed for Parkinson's Disease
  2023-05-16
• Poor bioavailability, is the liver or intestine to blame?
  2023-05-03
• Laser Doppler; new validated protocols revealed.
  2023-04-21
• Epilepsy models leading the way. Read on for results.
  2023-03-27
• Profiling anti-inflammatory drugs; from rodent to human
  2023-03-02
• The Mismatch Negativity Challenge
  2023-01-25
• Accelerate your drug discovery research. Proven science based results cost-effectively.
  2022-12-20
• Anxiety. Three preclinical tests; data revealed...
  2022-12-12
• Seven new posters, presented at SfN, now available to view.
  2022-11-23
• Name change announcement! News from the CEO.
  2022-11-04
• Chronic fatigue: different etiologies influence translational models
  2022-10-18
• Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
  2022-10-03
• Translational value increased with non-evoked pain measures.
  2022-09-21
• Rapid access to PK non-rodent studies. Leading expertise.
  2022-09-01
• Essential tremor research
  2022-08-19
• Can a psychedelic experience be modelled in rats?
  2022-08-01
• Gender Differences in Pain. New research revealed!
  2022-06-30
• New data on the effect of single dose psilocybin!
  2022-05-25
• From ketamine to psychedelics, join our webinar starting tomorrow!
  2022-05-09
• Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
  2022-04-05
• Accreditation awarded with flying colours
  2022-03-01
• Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
  2022-02-08
• Take a look! New posters, nine therapeutic areas available to view now.
  2021-12-01
• Nine new compelling studies to be revealed at SfN21!
  2021-11-03
• Can changes in EEG improve neuropathic pain treatments?
  2021-10-11
• 40Hz ASSR: sounds that change our thoughts about schizophrenia
  2021-08-31
• Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
  2021-08-09
• Translational endpoints for preclinical pain - improving your chances.
  2021-07-01
• Transpharmation aims for global standard. Let's talk about lab sustainability.
  2021-06-02
• Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
  2021-04-15
• Psilocybin: the power of mental reorganisation
  2020-12-06
• Expansion to world class premises
  2020-11-04
• Multiple therapeutic indications
  2020-10-05
• Focus on pain
  2020-09-04
• Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
  2020-03-08
• Announcing Transpharmation Poland!
  2020-02-08